PMC:7317273 / 24225-24706 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T152","span":{"begin":34,"end":38},"obj":"Body_part"},{"id":"T153","span":{"begin":39,"end":55},"obj":"Body_part"},{"id":"T154","span":{"begin":50,"end":55},"obj":"Body_part"},{"id":"T155","span":{"begin":220,"end":229},"obj":"Body_part"},{"id":"T156","span":{"begin":336,"end":340},"obj":"Body_part"}],"attributes":[{"id":"A152","pred":"fma_id","subj":"T152","obj":"http://purl.org/sig/ont/fma/fma7195"},{"id":"A153","pred":"fma_id","subj":"T153","obj":"http://purl.org/sig/ont/fma/fma66768"},{"id":"A154","pred":"fma_id","subj":"T154","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A155","pred":"fma_id","subj":"T155","obj":"http://purl.org/sig/ont/fma/fma84050"},{"id":"A156","pred":"fma_id","subj":"T156","obj":"http://purl.org/sig/ont/fma/fma7195"}],"text":"Schematic of SARS-CoV-2 infecting lung epithelial cells, and priming approaches to improve MSCs therapeutic efficacy for the treatment of COVID19 patients. (a) Represent a few priming approaches (priming by inflammatory cytokines and LPS, hypoxia pre-conditioning, (b) Primed MSCs, (c) SARS-CoV-2 and ‘Primed MSCs’ post-infusion in the lung, (d) Therapeutic effect exerted by MSCs (immunosuppression, reparative, angiogenesis, homing, anti-apoptotic, and anti-microbial activities)"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T48","span":{"begin":34,"end":38},"obj":"Body_part"},{"id":"T49","span":{"begin":336,"end":340},"obj":"Body_part"}],"attributes":[{"id":"A48","pred":"uberon_id","subj":"T48","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"A49","pred":"uberon_id","subj":"T49","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"}],"text":"Schematic of SARS-CoV-2 infecting lung epithelial cells, and priming approaches to improve MSCs therapeutic efficacy for the treatment of COVID19 patients. (a) Represent a few priming approaches (priming by inflammatory cytokines and LPS, hypoxia pre-conditioning, (b) Primed MSCs, (c) SARS-CoV-2 and ‘Primed MSCs’ post-infusion in the lung, (d) Therapeutic effect exerted by MSCs (immunosuppression, reparative, angiogenesis, homing, anti-apoptotic, and anti-microbial activities)"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T108","span":{"begin":13,"end":21},"obj":"Disease"},{"id":"T109","span":{"begin":138,"end":145},"obj":"Disease"},{"id":"T110","span":{"begin":286,"end":294},"obj":"Disease"}],"attributes":[{"id":"A108","pred":"mondo_id","subj":"T108","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A109","pred":"mondo_id","subj":"T109","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A110","pred":"mondo_id","subj":"T110","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"Schematic of SARS-CoV-2 infecting lung epithelial cells, and priming approaches to improve MSCs therapeutic efficacy for the treatment of COVID19 patients. (a) Represent a few priming approaches (priming by inflammatory cytokines and LPS, hypoxia pre-conditioning, (b) Primed MSCs, (c) SARS-CoV-2 and ‘Primed MSCs’ post-infusion in the lung, (d) Therapeutic effect exerted by MSCs (immunosuppression, reparative, angiogenesis, homing, anti-apoptotic, and anti-microbial activities)"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T261","span":{"begin":34,"end":55},"obj":"http://purl.obolibrary.org/obo/CL_0000082"},{"id":"T262","span":{"begin":157,"end":158},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T263","span":{"begin":170,"end":171},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T264","span":{"begin":266,"end":267},"obj":"http://purl.obolibrary.org/obo/CLO_0001021"},{"id":"T265","span":{"begin":336,"end":340},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T266","span":{"begin":336,"end":340},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T267","span":{"begin":470,"end":480},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"}],"text":"Schematic of SARS-CoV-2 infecting lung epithelial cells, and priming approaches to improve MSCs therapeutic efficacy for the treatment of COVID19 patients. (a) Represent a few priming approaches (priming by inflammatory cytokines and LPS, hypoxia pre-conditioning, (b) Primed MSCs, (c) SARS-CoV-2 and ‘Primed MSCs’ post-infusion in the lung, (d) Therapeutic effect exerted by MSCs (immunosuppression, reparative, angiogenesis, homing, anti-apoptotic, and anti-microbial activities)"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T94","span":{"begin":234,"end":237},"obj":"Chemical"}],"attributes":[{"id":"A94","pred":"chebi_id","subj":"T94","obj":"http://purl.obolibrary.org/obo/CHEBI_16412"},{"id":"A95","pred":"chebi_id","subj":"T94","obj":"http://purl.obolibrary.org/obo/CHEBI_52603"},{"id":"A96","pred":"chebi_id","subj":"T94","obj":"http://purl.obolibrary.org/obo/CHEBI_89981"}],"text":"Schematic of SARS-CoV-2 infecting lung epithelial cells, and priming approaches to improve MSCs therapeutic efficacy for the treatment of COVID19 patients. (a) Represent a few priming approaches (priming by inflammatory cytokines and LPS, hypoxia pre-conditioning, (b) Primed MSCs, (c) SARS-CoV-2 and ‘Primed MSCs’ post-infusion in the lung, (d) Therapeutic effect exerted by MSCs (immunosuppression, reparative, angiogenesis, homing, anti-apoptotic, and anti-microbial activities)"}

{"project":"LitCovid-PubTator","denotations":[{"id":"345","span":{"begin":13,"end":23},"obj":"Species"},{"id":"346","span":{"begin":146,"end":154},"obj":"Species"},{"id":"347","span":{"begin":286,"end":296},"obj":"Species"},{"id":"348","span":{"begin":234,"end":237},"obj":"Chemical"},{"id":"349","span":{"begin":138,"end":145},"obj":"Disease"}],"attributes":[{"id":"A345","pred":"tao:has_database_id","subj":"345","obj":"Tax:2697049"},{"id":"A346","pred":"tao:has_database_id","subj":"346","obj":"Tax:9606"},{"id":"A347","pred":"tao:has_database_id","subj":"347","obj":"Tax:2697049"},{"id":"A348","pred":"tao:has_database_id","subj":"348","obj":"MESH:D008070"},{"id":"A349","pred":"tao:has_database_id","subj":"349","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Schematic of SARS-CoV-2 infecting lung epithelial cells, and priming approaches to improve MSCs therapeutic efficacy for the treatment of COVID19 patients. (a) Represent a few priming approaches (priming by inflammatory cytokines and LPS, hypoxia pre-conditioning, (b) Primed MSCs, (c) SARS-CoV-2 and ‘Primed MSCs’ post-infusion in the lung, (d) Therapeutic effect exerted by MSCs (immunosuppression, reparative, angiogenesis, homing, anti-apoptotic, and anti-microbial activities)"}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T30","span":{"begin":413,"end":425},"obj":"http://purl.obolibrary.org/obo/GO_0001525"}],"text":"Schematic of SARS-CoV-2 infecting lung epithelial cells, and priming approaches to improve MSCs therapeutic efficacy for the treatment of COVID19 patients. (a) Represent a few priming approaches (priming by inflammatory cytokines and LPS, hypoxia pre-conditioning, (b) Primed MSCs, (c) SARS-CoV-2 and ‘Primed MSCs’ post-infusion in the lung, (d) Therapeutic effect exerted by MSCs (immunosuppression, reparative, angiogenesis, homing, anti-apoptotic, and anti-microbial activities)"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T30","span":{"begin":239,"end":246},"obj":"Phenotype"}],"attributes":[{"id":"A30","pred":"hp_id","subj":"T30","obj":"http://purl.obolibrary.org/obo/HP_0012418"}],"text":"Schematic of SARS-CoV-2 infecting lung epithelial cells, and priming approaches to improve MSCs therapeutic efficacy for the treatment of COVID19 patients. (a) Represent a few priming approaches (priming by inflammatory cytokines and LPS, hypoxia pre-conditioning, (b) Primed MSCs, (c) SARS-CoV-2 and ‘Primed MSCs’ post-infusion in the lung, (d) Therapeutic effect exerted by MSCs (immunosuppression, reparative, angiogenesis, homing, anti-apoptotic, and anti-microbial activities)"}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T405","span":{"begin":13,"end":23},"obj":"SP_7"},{"id":"T406","span":{"begin":34,"end":38},"obj":"CL:0000082;UBERON:0002048"},{"id":"T407","span":{"begin":39,"end":49},"obj":"UBERON:0000115;CL:0000066"},{"id":"T408","span":{"begin":50,"end":55},"obj":"CL:0000066"},{"id":"T409","span":{"begin":91,"end":95},"obj":"DG_47"},{"id":"T410","span":{"begin":138,"end":145},"obj":"SP_7"},{"id":"T411","span":{"begin":234,"end":237},"obj":"CHEBI:16412;CHEBI:16412"},{"id":"T412","span":{"begin":276,"end":280},"obj":"DG_47"},{"id":"T413","span":{"begin":286,"end":296},"obj":"SP_7"},{"id":"T414","span":{"begin":309,"end":313},"obj":"DG_47"},{"id":"T415","span":{"begin":336,"end":340},"obj":"UBERON:0002048"},{"id":"T416","span":{"begin":376,"end":380},"obj":"DG_47"},{"id":"T417","span":{"begin":413,"end":425},"obj":"GO:0001525"},{"id":"T1052","span":{"begin":138,"end":145},"obj":"SP_7"}],"text":"Schematic of SARS-CoV-2 infecting lung epithelial cells, and priming approaches to improve MSCs therapeutic efficacy for the treatment of COVID19 patients. (a) Represent a few priming approaches (priming by inflammatory cytokines and LPS, hypoxia pre-conditioning, (b) Primed MSCs, (c) SARS-CoV-2 and ‘Primed MSCs’ post-infusion in the lung, (d) Therapeutic effect exerted by MSCs (immunosuppression, reparative, angiogenesis, homing, anti-apoptotic, and anti-microbial activities)"}